Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2026
Efficacy of diquafosol 3% in preventing and treating dry eye associated with pediatric orthokeratology.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Lili, Hou Wenbin, Ying Peixi, Gao Na, Fan Xinyi, Li Yingli
Аннотация
PURPOSE: To evaluate the efficacy of diquafosol 3% in preventing and treating dry eye associated with orthokeratology in children.
METHODS: First-time pediatric orthokeratology wearers were enrolled in this prospective, randomized clinical trial. Participants were randomized into the treatment group (3% diquafosol sodium four times daily from the prefitting period) and control group (no additional treatment). Noninvasive tear film parameters (first break-up time [NIBUT], average NIBUT, tear meniscus height, and lipid layer thickness), corneal staining grade, uncorrected visual acuity (UCVA), and Ocular Surface Disease Index (OSDI) were compared at baseline, before lens wear, and at 1 week, 1 month, and 3 months.
RESULTS: A total of 64 children (128 eyes) completed the study. During the prefitting period, all tear film parameters improved significantly in the treatment group (all P < 0.001). At 3 months, the treatment group demonstrated significantly higher first NIBUT, average NIBUT, tear meniscus height, and lipid layer thickness (all P < 0.001), with lower OSDI scores (P < 0.05) and higher UCVA (P < 0.001). Corneal staining was significantly lower in the treatment group at 1 week (P < 0.05) but not at 1 or 3 months. Mild adverse events included transient discharge (3 children, treatment group) and conjunctival congestion (5 eyes, control group). There were no serious adverse events.
CONCLUSIONS: Prophylactic and therapeutic use of diquafosol 3% improved tear film stability, tear secretion, and dry eye symptoms in children undergoing orthokeratology. Early initiation during the prefitting period may establish a more favorable ocular surface before lens wear.
METHODS: First-time pediatric orthokeratology wearers were enrolled in this prospective, randomized clinical trial. Participants were randomized into the treatment group (3% diquafosol sodium four times daily from the prefitting period) and control group (no additional treatment). Noninvasive tear film parameters (first break-up time [NIBUT], average NIBUT, tear meniscus height, and lipid layer thickness), corneal staining grade, uncorrected visual acuity (UCVA), and Ocular Surface Disease Index (OSDI) were compared at baseline, before lens wear, and at 1 week, 1 month, and 3 months.
RESULTS: A total of 64 children (128 eyes) completed the study. During the prefitting period, all tear film parameters improved significantly in the treatment group (all P < 0.001). At 3 months, the treatment group demonstrated significantly higher first NIBUT, average NIBUT, tear meniscus height, and lipid layer thickness (all P < 0.001), with lower OSDI scores (P < 0.05) and higher UCVA (P < 0.001). Corneal staining was significantly lower in the treatment group at 1 week (P < 0.05) but not at 1 or 3 months. Mild adverse events included transient discharge (3 children, treatment group) and conjunctival congestion (5 eyes, control group). There were no serious adverse events.
CONCLUSIONS: Prophylactic and therapeutic use of diquafosol 3% improved tear film stability, tear secretion, and dry eye symptoms in children undergoing orthokeratology. Early initiation during the prefitting period may establish a more favorable ocular surface before lens wear.